<SUBMISSION>
<ACCESSION-NUMBER>0000891836-00-000738
<TYPE>SC TO-T/A
<PUBLIC-DOCUMENT-COUNT>2
<FILING-DATE>20001213
<GROUP-MEMBERS>KONINKLIJKE PHILIPS ELECTRONICS NV
<GROUP-MEMBERS>PHILIPS HOLDING USA INC.
<GROUP-MEMBERS>PHILIPS MEDICAL ACQUISITION CORPORATION
<SUBJECT-COMPANY>
<COMPANY-DATA>
<CONFORMED-NAME>ADAC LABORATORIES
<CIK>0000313798
<ASSIGNED-SIC>3844
<IRS-NUMBER>941725806
<STATE-OF-INCORPORATION>CA
<FISCAL-YEAR-END>0930
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>SC TO-T/A
<ACT>34
<FILE-NUMBER>005-32403
<FILM-NUMBER>788450
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>540 ALDER DR
<CITY>MILPITAS
<STATE>CA
<ZIP>95035
<PHONE>4083219100
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>540 ALDER DR
<CITY>MILPITAS
<STATE>CA
<ZIP>95035
</MAIL-ADDRESS>
</SUBJECT-COMPANY>
<FILED-BY>
<COMPANY-DATA>
<CONFORMED-NAME>KONINKLIJKE PHILIPS ELECTRONICS NV
<CIK>0000313216
<ASSIGNED-SIC>3600
<STATE-OF-INCORPORATION>P7
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>SC TO-T/A
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>REMBRANDT TOWER AMSTELPLEIN 1
<STREET2>1096 HA AMSTERDAM
<CITY>THE NETHERLANDS
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>REMBRANDT TOWER AMSTELPLEIN 1
<STREET2>1096 HA AMSTERDAM
<CITY>THE NETHERLANDS
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>PHILIPS ELECTRONICS N V
<DATE-CHANGED>19930727
</FORMER-COMPANY>
</FILED-BY>
<DOCUMENT>
<TYPE>SC TO-T/A
<SEQUENCE>1
<FILENAME>0001.htm
<DESCRIPTION>SCHEDULE TO, AMENDMENT NO. 7
<TEXT>

<HTML>
<HEAD>
<TITLE>
SCHEDULE TO, AMENDMENT NO. 7
</TITLE>
</HEAD>
<BODY>

<P ALIGN=CENTER>
<FONT SIZE=-1><B>As filed with the Securities and Exchange Commission on
December 13, 2000</B></FONT>
</P>

<TABLE WIDTH=30%  ALIGN=RIGHT CELLPADDING=2 CELLSPACING=0 BORDER=2>
<TR>
     <TD ALIGN=CENTER>
     <B><FONT SIZE=-1>OMB APPROVAL</FONT></B>
     </TD>
</TR>
<TR>
     <TD>
     <B><FONT SIZE=-1>OMB Number: 3235-0515</FONT></B>
     </TD>
</TR>
<TR>
     <TD>
     <B><FONT SIZE=-1>Expires: January 31, 2002</FONT></B>
     </TD>
</TR>
<TR>
     <TD>
     <B><FONT SIZE=-1>Estimated average burden <BR>
     hours per response: 43.5</FONT></B>
     </TD>
</TR>
</TABLE>

<BR><BR><BR><BR><BR><BR><BR><BR>

<P ALIGN=CENTER>
<B><FONT SIZE=+1>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</FONT><BR>
Washington, D.C. 20549</B>
</P>

<P ALIGN=CENTER>
<FONT SIZE=+1><B>Schedule TO</B></FONT>
</P>

<P ALIGN=CENTER>
<B>Tender Offer Statement under Section 14(d)(1) or 13(e)(1)<BR>
of the Securities Exchange Act of 1934</B>
</P>

<P ALIGN=CENTER>
<B>(Amendment No. 7)</B>
</P>

<P ALIGN=CENTER>
<B>ADAC Laboratories<BR>
<BR>
<FONT SIZE=-2>(Name of Subject Company (Issuer))</FONT></B>
</P>

<P ALIGN=CENTER>
<B>Philips Medical Acquisition Corporation<BR>
<BR>
a Wholly Owned Subsidiary of<BR>
<BR>
Philips Holding USA Inc.<BR>
<BR>
a Wholly Owned Subsidiary of<BR>
<BR>
Koninklijke Philips Electronics N.V.<BR>
<BR>
<FONT SIZE=-2>(Names of Filing Persons)</FONT></B>

<P ALIGN=CENTER>
<B>COMMON STOCK,<BR>
NO PAR VALUE<BR>
<BR>
<FONT SIZE=-2>(Title of Class of Securities)</FONT></B>
</P>

<P ALIGN=CENTER>
<B><FONT SIZE=-2>005313200<BR>
<BR>
(CUSIP Number of Class of Securities)</FONT></B>
</P>

<P ALIGN=CENTER>
<B><FONT SIZE=-2>William E. Curran<BR>
<BR>
President<BR>
<BR>
Philips Holding USA Inc.<BR>
<BR>
1251 Avenue of the Americas<BR>
<BR>
New York, New York 10020</FONT></B>
</P>

<P ALIGN=CENTER>
<B><FONT SIZE=-2>(Name, address, and telephone numbers of person authorized<BR>
to receive notices and communications on behalf of filing persons)</FONT></B>
</P>

<P ALIGN=CENTER>
<FONT SIZE=-1>with a copy to:</FONT>
</P>

<P ALIGN=CENTER>
<B><FONT SIZE=-1>Matthew G. Hurd<BR>
Sullivan &amp; Cromwell<BR>
125 Broad Street<BR>
New York, New York 10004-2498<BR>
(212) 558-4000</FONT></B>
</P>

<P>&nbsp;</P>
<P>&nbsp;</P>
<HR NOSHADE SIZE=4>
<PAGE>

<P>&nbsp;</P>

<P>&nbsp;</P>

<HR SIZE=1 NOSHADE>

<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR>
     <TH COLSPAN=2>CALCULATION OF FILING FEE</TH>
</TR>
<TR>
     <TD WIDTH=50%>&nbsp;</TD>
     <TD WIDTH=50%>&nbsp;</TD>
</TR>
<TR>
     <TD ALIGN=CENTER>Transaction valuation <SUP>(1)</SUP></TD>
     <TD ALIGN=CENTER>Amount of filing fee<SUP>(2)</SUP></TD>
</TR>
<TR>
     <TD ALIGN=CENTER>$489,852,842</TD>
     <TD ALIGN=CENTER>$97,971</TD>
</TR>
</TABLE>

<HR SIZE=1 NOSHADE>

<P>
(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on the offer to
purchase all of the outstanding shares of common stock of ADAC Laboratories
together with the associated rights to purchase Series A Junior Participating
Preferred Stock at a purchase price of $18.50 cash per share, 21,136,116 shares
outstanding and outstanding options with respect to 5,342,416 shares, in each
case as of November 12, 2000.
</P>
<P>
(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1% of 1/50<SUP>th</SUP>
of the transaction valuation.
</P>

<P>
[X]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check the box if any
part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing
with which the offsetting fee was previously paid. Identify the previous filing
by registration statement number, or the Form or Schedule and the date of its
filing.<BR> Amount Previously Paid: $97,971<BR> Form or Registration No.:
005-32403<BR> Filing Party: Koninklijke Philips Electronics N.V.<BR> Date Filed:
November 14, 2000
</P>

<P>
[_]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check the box if the
filing relates solely to preliminary communications made before the commencement
of a tender offer.

<P>
Check the appropriate boxes below to designate any transactions to which the
statement relates:<BR>
[X]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;third-party tender
offer subject to Rule 14d-1.<BR>
[_]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;issuer tender offer
subject to Rule 13e-4.<BR>
[_]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;going-private
transaction subject to Rule 13e-3.<BR>
[_]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;amendment to Schedule
13D under Rule 13d-2.

<P>
Check the following box if the filing is a final amendment reporting the results
of the tender offer:&nbsp;&nbsp;&nbsp;[_]
</P>

<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
This Amendment No. 7 ("Amendment No. 7") to Schedule TO amends and supplements
the Schedule TO filed with the Securities and Exchange Commission ("SEC") on
November 14, 2000 (the "Original Schedule TO"), as amended by Amendment No. 1,
Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment No. 5 and Amendment
No. 6 to the Original Schedule TO (collectively, the "Schedule TO"), by
Koninklijke Philips Electronics N.V., Philips Holding USA Inc. and Philips
Medical Acquisition Corporation ("Merger Sub") relating to the tender offer (the
"Offer") commenced by Merger Sub, on November 14, 2000 to purchase all of the
outstanding shares of common stock, no par value, of ADAC Laboratories ("ADAC")
together with the associated rights to purchase Series A Junior Participating
Preferred Stock of ADAC, no par value, at a price of $18.50 per share, net to
the sellers in cash, upon the terms and subject to the conditions set forth in
the Offer to Purchase, dated November 14, 2000, and the related Letter of
Transmittal.
</P>

<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The information in the Schedule TO is hereby expressly incorporated herein by
reference in response to all the items of this Amendment No. 7, except as
otherwise set forth below. Capitalized terms used but not defined herein shall
have the meaning ascribed to them in the Original Schedule TO.
</P>

<P>&nbsp;</P>
<P ALIGN=CENTER>1</P>
<HR NOSHADE SIZE=4>
<PAGE>

<P>&nbsp;</P>
<P>&nbsp;</P>

<H4 ALIGN=LEFT>
Item 11.&nbsp;&nbsp;&nbsp;Additional Information.
</H4>

<P>
Item 11 of the Schedule TO is hereby amended and supplemented to include the
following paragraph:
</P>

<P>
The expiration date of the tender offer has been extended to 5:00 p.m., New York
City time, on Friday, December 15, 2000, unless further extended. In addition on
December 13, 2000, Royal Philips issued a press release announcing the extension
of the tender offer, which is attached as an exhibit hereto and incorporated
herein by reference.
</P>


<H4 ALIGN=LEFT>
Item 12.&nbsp;&nbsp;&nbsp;Exhibits.
</H4>

<P>
Item 12 of the Schedule TO is hereby amended and supplemented to include the
following exhibit:
</P>

<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=15%>99(a)(16)</TD>
<TD WIDTH=85%>      Text of press release issued by Royal Philips on December 13,
                    2000.<BR><BR></TD>
</TR>
</TABLE>

<P>&nbsp;</P>
<P ALIGN=CENTER>2</P>
<HR NOSHADE SIZE=4>
<PAGE>

<P>&nbsp;</P>
<P>&nbsp;</P>

<P ALIGN=CENTER>
<B>SIGNATURE</B>
</P>

<P>After due inquiry and to
the best of our knowledge and belief, we certify that the information set forth
in this statement is true, complete and correct. </P>

<P>Date: December 13, 2000</P>

<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR>
     <TD WIDTH=45%> </TD>
     <TD WIDTH=55%> </TD>
</TR>
<TR>
     <TD>&nbsp;&nbsp;</TD>
     <TD>                        <B>PHILIPS MEDICAL ACQUISITION CORPORATION</B><BR>
<BR><BR>
                                 By: &nbsp;&nbsp;<U>/s/ Belinda W. Chew</U><BR>
                                 Name:&nbsp;&nbsp;Belinda W. Chew<BR>
                                 Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vice President <BR><BR><BR></TD>
</TR>
<TR>
     <TD>&nbsp;&nbsp;</TD>
     <TD>                        <B>PHILIPS HOLDING USA INC.</B><BR>
<BR><BR>
                                 By: &nbsp;&nbsp;<U>/s/ Belinda W. Chew</U><BR>
                                 Name:&nbsp;&nbsp;Belinda W. Chew<BR>
                                 Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Senior Vice President <BR><BR><BR></TD>
</TR>
<TR>
     <TD>&nbsp;&nbsp;</TD>
     <TD>                        <B>KONINKLIJKE PHILIPS ELECTRONICS N.V.</B><BR>
<BR><BR>
                                 By: &nbsp;&nbsp;<U>/s/ Cor Boonstra</U><BR>
                                 Name:  &nbsp;&nbsp;Cor Boonstra<BR>
                                 Title: &nbsp;&nbsp;&nbsp;&nbsp;
                                        President, Chairman of the Board of Management<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                        and the Group Management Committee<BR><BR><BR></TD>
</TR>
<TR>
     <TD>&nbsp;&nbsp;</TD>
     <TD>                        By: <U>/s/ Jan H.M. Hommen</U><BR>
                                 Name:  &nbsp;&nbsp;Jan H.M. Hommen<BR>
                                 Title: &nbsp;&nbsp;&nbsp;&nbsp;
                                        Executive Vice-President, Chief Financial<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                        Officer, Member of the Board of Management<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                        and the Group Management Committee<BR><BR></TD>
</TR>
</TABLE>

<P>&nbsp;</P>
<P>&nbsp;</P>
<HR NOSHADE SIZE=4>
<PAGE>
<P>&nbsp;</P>
<P>&nbsp;</P>

<P ALIGN=CENTER>
EXHIBIT INDEX
</P>

<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=BOTTOM>
<TD WIDTH=15%>EXHIBIT<BR>
              <U>NUMBER</U></TD>
<TD WIDTH=85%><U>EXHIBIT DESCRIPTION</U></TD>
</TR>

<TR VALIGN=BOTTOM>
<TD WIDTH=15%>&nbsp;</TD>
<TD WIDTH=85%>&nbsp;</TD>
</TR>


<TR VALIGN=TOP>
<TD WIDTH=15%>99(a)(16)</TD>
<TD WIDTH=85%>     Text of press release issued by Royal Philips on December 13,
                   2000.<BR><BR></TD>
</TR>
</TABLE>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(A).(16)
<SEQUENCE>2
<FILENAME>0002.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>


<HTML>
<HEAD>
<TITLE>
Press Release
</TITLE>
</HEAD>

<BODY>


<P ALIGN=RIGHT><FONT SIZE=2>
                                                               EXHIBIT 99(a)(16)
</FONT></P>

<P><FONT SIZE=2>
<B>PHILIPS EXTENDS TENDER OFFER FOR SHARES OF ADAC LABORATORIES TO FRIDAY
DECEMBER 15, 2000; NO ANTITRUST OBSTACLES TO COMPLETING TENDER
OFFER</B></FONT></P>

<P>
<FONT SIZE=2><B>88.5% OF FULLY DILUTED SHARES SO FAR TENDERED OR COVERED BY
GUARANTEED DELIVERY NOTICES</B></FONT>
</P>

<P>
<FONT SIZE=2><B>Amsterdam, the Netherlands - December 13, 2000</B>: Royal
Philips Electronics (AEX: PHI, NYSE: PHG) announced today that it has extended
the expiration date of its $18.50 per share cash tender offer for all of the
outstanding shares of common stock of ADAC Laboratories (NASDAQ: ADAC), until
5:00 p.m., New York City time, on Friday, December 15, 2000.</FONT>
</P>

<P>
<FONT SIZE=2>As of 12:00 midnight, New York City time, on Tuesday, December 12,
2000, approximately 17,558,749 ADAC shares had been validly tendered and not
withdrawn pursuant to the tender offer. In addition, notices of guaranteed
delivery with respect to approximately 1,954,509 ADAC shares had been received
by the depositary for the offer. The shares tendered and not withdrawn and the
shares as to which notices of guaranteed delivery have been received represent
in the aggregate approximately 88.5% of the total outstanding shares of ADAC
common stock on a fully diluted basis, calculated in accordance with the merger
agreement.
</FONT>
</P>

<P>
<FONT SIZE=2>The tender offer commenced on November 14, 2000 and is now
scheduled to expire at 5:00 p.m., New York City time, on Friday, December 15,
2000, unless further extended. </FONT>
</P>

<P>
<FONT SIZE=2>Pursuant to the terms of the merger agreement, Philips may extend
the offer one or more times up to a maximum of ten business days. If as of such
tenth business day there have not been validly tendered at least 90% of the
outstanding shares of common stock of ADAC Laboratories, calculated on a fully
diluted basis, then Philips has a number of options. It must either amend the
offer to reduce the number of shares subject to the offer to 49.90% of the
outstanding shares of ADAC common stock (in which case Philips would cause ADAC
to call a shareholders&#146; meeting after completion of the amended offer for
the purpose of securing approval of the merger and the merger agreement by a
majority vote of the ADAC shareholders). Or Philips must amend the offer in
contemplation of the exercise of an option that ADAC has granted to Philips,
which will permit Philips to purchase that number of shares of ADAC common
stock, which, when combined with shares of common stock of ADAC issuable upon
exercise of the option, equals 90.1% of the ADAC shares then outstanding
calculated on a fully diluted basis. In the event that Philips acquires more
than 90% of the outstanding ADAC shares, it will be able to effect the merger
without a vote of ADAC&#146;s shareholders. </FONT>
</P>

<P>
<FONT SIZE=2>As previously announced, the waiting period in the USA applicable
to the transaction under the Hart-Scott-Rodino Antitrust Improvements Act has
expired and Philips has in the mean time been advised that German antitrust
clearance has been obtained. </FONT>
</P>

<P>
<FONT SIZE=2>Antitrust filings have also been made in Austria, Brazil and Italy.
None of these jurisdictions will prohibit Philips from purchasing any shares
pursuant to the offer, although local post-closing implementation may need to be
postponed with regard to some of these jurisdictions until local clearance is
received.</FONT>
</P>

<P>
<FONT SIZE=2><I>For further information:<BR>
Ben Geerts, Philips Corporate Communications, tel: +31 20 5977215<BR>
Linda Snyder, ADAC Laboratories, tel: +1&nbsp;408&nbsp;468&nbsp;3750</I></FONT>
</P>

<P>
<FONT SIZE=2><U>ADAC Laboratories</U> is a worldwide market leader in nuclear
medicine imaging equipment and radiation therapy planning systems. The company
offers a broad range of nuclear medicine systems that are used primarily in the
diagnosis of heart disease and cancer. In addition, ADAC Laboratories is an
emerging leader in positron emission tomography (PET) imaging. PET provides
physicians with solutions for accurate cancer disease management. The market for
PET systems has grown dramatically in the past year due to expanded Medicare
reimbursement, and the widespread acceptance of PET in the U.S.A. for cancer
diagnosis, staging and treatment follow-up. </FONT>
</P>

<P>
<FONT SIZE=2>Royal Philips Electronics of the Netherlands is one of the
world&#146;s biggest electronics companies and Europe&#146;s largest, with sales
of EUR 31.5 billion in 1999. It is a global leader in color television sets,
lighting, electric shavers, color picture tubes for televisions and monitors,
and one-chip TV products. Its 239,370 employees in more than 60 countries are
active in the areas of lighting, consumer electronics, domestic appliances,
components, semiconductors and medical systems. Philips is quoted on the NYSE
(symbol: PHG), London, Frankfurt, Amsterdam and other stock exchanges. News from
Philips is located at <U>www.news.philips.com</U></FONT>
</P>

<P>
<FONT SIZE=2><U>Philips Medical Systems</U> is a leader in diagnostic imaging
and related services and offers a robust portfolio, including Catheterization
Labs, MR, CT, X-ray, and ultrasound systems, as well as information technology
solutions that address the radiology, general imaging, surgical and
cardiovascular markets. </FONT>
</P>

<P>
<FONT SIZE=2><I>ADAC Laboratories&#146; shareholders are advised to read the
tender offer statement regarding the business combination between ADAC
Laboratories and Philips referred to in the news release above, which was filed
by Philips Holding USA Inc. and Philips Medical Acquisition Corporation,
wholly-owned subsidiaries of Philips, with the U.S. Securities and Exchange
Commission, and the related solicitation/recommendation statement that was filed
by ADAC Laboratories with the Commission. The tender offer statement (including
an offer to purchase, letter of transmittal and related tender offer documents)
and the solicitation/recommendation statement contain important information that
should be read carefully before any decision is made with respect to the tender
offer. These documents have been made available to all holders of ADAC
Laboratories common stock at no expense to them. These documents are also
available at no charge at the SEC web site at www.sec.gov. The press release
above is neither an offer to purchase nor a solicitation of an offer to sell
securities of ADAC Laboratories. The tender offer is made solely by an offer to
purchase and related letter of transmittal as disseminated upon the commencement
of the tender offer.</I></FONT>
</P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SUBMISSION>
